Women Health Care Market Forecast to 2028 - COVID-..
Women Health Care Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Drug (XGEVA, Mirena, EVISTA, Prolia, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, Premarin, FORTEO, ACTONEL, and Others); Application (Postmenopausal Osteoporosis, Menopause, Endometriosis, Hormonal Infertility, Contraceptives, and Other); Distribution Channel (Hospital Pharmacies, Drug Stores and Retail pharmacies, and Online Providers), and Geography
Women's healthcare includes complete emphasis and focuses on the wellbeing of the women by ensuring appropriate diagnosis and treatment. Women experience various problems during and postmenstrual cycle, which is common amongst women. Furthermore, the most prevalent diseases among women include various urological disorders, polycystic ovarian syndrome, and other post-menopausal complications. Multiple medications are available for controlling birth and regulating hormones, which is a significant challenge. During pregnancy and post-pregnancy, the hormonal disturbances are experienced by most women, the management of which is essential and is in demand for the next few years.
The "Global Women Health Care Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Women health care market with detailed market segmentation by drug, application, distribution channel, and geography. The report provides key statistics on the market status of the leading Women health care market players and offers key trends and opportunities in the market.
- Based on drug, the global Women health care market is segmented into xgeva, mirena, evista, prolia, zometa, reclast/aclasta, minastrin 24 fe, nuvaring, premarin, forteo, actonel, and others.
- On the basis of application, the market is segmented into postmenopausal osteoporosis, menopause, endometriosis, hormonal infertility, contraceptives, and other.
- On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online providers.
- Rise in the incidences of chronic health condition among women.
- Rise in the demand for contraceptives to prevent unintended pregnancies.
- Increasing government initiatives to control population growth.
- The harmful effects of women healthcare products are the major restraining factor for this market.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Women health care market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
BThe report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Women health care market in these regions.
IMPACT OF COVID-19 ON WOMEN HEALTH CARE MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
The report covers key developments in the Women health care market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Women health care market are anticipated to lucrative growth opportunities in the future with the rising demand for Women health care in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Women health care market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Bayer AG
- Merck & Co.
- Pfizer Inc.
- Agile Therapeutics Inc.
- Ferring Pharmaceuticals
- Mylan N.V.
- Blairex Laboratories
The Insight Partner's dediWomen health careed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The List of Companies
1. Bayer AG
3. Merck & Co.
4. Pfizer Inc.
6. Agile Therapeutics Inc.
7. Ferring Pharmaceuticals
8. Mylan N.V.
10. Blairex Laboratories
11. Apothecus Pharmaceutical
12. Eli Lilly and Company
13. Novartis AG
14. Johnson & Johnson
16. Bristol-Myers Squib